Unichem gets USFDA approval to sell prostate drug
New Delhi: Drug firm Unichem Laboratories has received approval from the US health regulator to market alfuzosin hydrochloride extended release tablets, used in treating prostatic hyperlasia, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) for alfuzosin hydrochloride extended release tablets, a generic version of Concordia Pharmaceuticals Ins's Uroxatral extended release tablets, Unichem Laboratories said in a regulatory filing.
The tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperlasia in adults.
"The product will be commercialised from Unichem's Goa plant. The active pharmaceutical ingredients (API) for the product would also be made in-house at Pithampur plant," the company said.
Unichem now has a total of 20 abbreviated new drug application (ANDA) approvals from the USFDA.
The company has received final approval from the US Food and Drug Administration (USFDA) for alfuzosin hydrochloride extended release tablets, a generic version of Concordia Pharmaceuticals Ins's Uroxatral extended release tablets, Unichem Laboratories said in a regulatory filing.
The tablets are indicated for the treatment of signs and symptoms of benign prostatic hyperlasia in adults.
"The product will be commercialised from Unichem's Goa plant. The active pharmaceutical ingredients (API) for the product would also be made in-house at Pithampur plant," the company said.
Unichem now has a total of 20 abbreviated new drug application (ANDA) approvals from the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.